OraSure Technologies Teams With The Reed For Hope Foundation, Singer/Songwriter/Actress Keri Hilson and Dr. Rachael Ross to Encourage America to Get Tested for HIV

company logo

BETHLEHEM, Pa., June 26, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it has teamed up with The Reed For Hope Foundation and their new ambassador, award-winning singer/songwriter/actress Keri Hilson, and medical doctor and sexologist Dr. Rachael Ross, to encourage individuals to get tested for HIV on National HIV Testing Day on June 27th using the new OraQuick® In-Home HIV Test.

National HIV Testing Day is an annual observance created to encourage Americans to get tested for the HIV virus. This year marks the first observance of National HIV Testing Day when consumers have the option of purchasing the OraQuick® In-Home HIV Test – the only FDA-approved over-the-counter rapid HIV test, which now empowers consumers to get tested with the same test used by healthcare professionals.

OraQuick® In-Home HIV Test Educational Campaign Media Tour

As part of its ongoing educational and awareness efforts, OraSure has teamed up with The Reed For Hope Foundation and its "Love Healthy" campaign which encourages loved ones to be healthy and test for HIV.

The Reed For Hope Foundation (RFHF), which was founded by Emmy Award Winning Casting Director Robi Reed, aims to raise awareness, gather resources, and build alliances with other charities and organizations in the fight to stop preventable diseases like HIV, eliminate health disparities and inspire general wellness.

RFHF's Love Healthy Ambassador Keri Hilson and Dr. Rachael Ross will be making media appearances in New York City on June 26th and 27th in support of the campaign. The tour is part of an integrated marketing program that includes events, as well as national and local radio, outdoor, television, print and digital advertising.

"We are honored to be working with Ms. Hilton and Dr. Ross, The Reed For Hope Foundation, and so many dedicated state and local organizations to raise awareness of the importance of HIV testing, and help reduce the fear and stigma often associated with testing," said Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies. "Now consumers have direct access to the OraQuick In-Home HIV Test – the same test healthcare professionals have used for years. They can now learn their HIV status in the privacy of their own homes."

2013 National HIV Testing Day Consumer Perception/Attitude Survey

OraSure also released the results from its "2013 National HIV Testing Day Consumer Perception/Attitude Survey," which surveyed 1,000 sexually active adults on perception of risk for HIV and common barriers to getting tested for HIV.

The survey found wide disparities between HIV risk perception and behavior among the consumers surveyed, and underscored the need for more education and awareness around HIV testing. More information and key findings of the OraQuick National HIV Testing Day Survey can be found at http://www.oraquick.com/media.

According to the Centers for Disease Control and Prevention (CDC), there are approximately 1.2 million people in the U.S. that have HIV and approximately 240,000 of them are unaware of their status. Those who do not know they are HIV positive are disproportionately responsible for the 50,000 new HIV infections that occur each year.

Approved by the U.S. Food and Drug Administration (FDA) in July 2012, the OraQuick® In-Home HIV Test is the first rapid infectious disease test ever to be made available directly to consumers for in-home use. The OraQuick® In-Home Test was named one of the "Best Inventions of 2012" by TIME and was also named a "Top Health Breakthrough of 2012" by Men's Health magazine. The product is an over-the-counter version of the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test, an oral swab rapid HIV test with more than 25 million units sold in the professional market, including doctors, hospitals, clinics and other trained professionals.

To ensure optimal support for individuals using the OraQuick® In-Home HIV Test, OraSure offers live support and comprehensive referral services 24 hours a day, seven days a week, every day of the year, through a toll-free support center and comprehensive consumer website at www.oraquick.com. The OraQuick® Support Center is staffed with highly trained, bi-lingual (English/Spanish) representatives who are available by telephone at 866-436-6527 to answer questions about HIV/AIDS and using and interpreting the test. They also provide referrals to follow-up and care, and can take orders for the OraQuick In-Home HIV Test. Additionally, the product website provides access to resources and referral to follow-up counseling, confirmatory testing and medical care.

For more information on the OraQuick® In-Home HIV Test, visit www.OraQuick.com.

About OraSure Technologies

OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions for detecting various drugs of abuse. In July 2012, the Company received approval from the U.S. Food and Drug Administration for the Company's OraQuick® In-Home HIV Test for sale directly to consumers in the over-the-counter (OTC) market - making it the first and only rapid OTC HIV test approved in the U.S. In addition, the Company is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, and commercial and industrial entities. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.

For more information on OraSure Technologies, please visit www.orasure.com.

CONTACT: Media Contact: Jennifer Moritz Zer0 to 5ive for OraSure Technologies 917-748-4006 jmoritz@0to5.com

Source:OraSure Technologies, Inc.